| scholarly article | Q13442814 |
| P356 | DOI | 10.1074/JBC.M100743200 |
| P698 | PubMed publication ID | 11335715 |
| P50 | author | David L. Narum | Q55174557 |
| P2093 | author name string | Chen DH | |
| Liang H | |||
| Sim BK | |||
| Holland-Linn J | |||
| Plum SM | |||
| Fuhrmann SR | |||
| MacDonald NJ | |||
| Shivers WY | |||
| Wingard JN | |||
| P2860 | cites work | Endostatin: an endogenous inhibitor of angiogenesis and tumor growth | Q24315369 |
| Troponin I is present in human cartilage and inhibits angiogenesis | Q24674047 | ||
| Tumor angiogenesis: therapeutic implications | Q27860595 | ||
| Functional properties of non-muscle tropomyosin isoforms | Q28252521 | ||
| What Is the Evidence That Tumors Are Angiogenesis Dependent? | Q29620029 | ||
| Fibronectin controls capillary endothelial cell growth by modulating cell shape | Q33572594 | ||
| Cloning, expression, and in vitro activity of human endostatin | Q33862216 | ||
| Angiostatin and endostatin: endogenous inhibitors of tumor growth | Q34146320 | ||
| Autocrine activities of basic fibroblast growth factor: regulation of endothelial cell movement, plasminogen activator synthesis, and DNA synthesis | Q36219574 | ||
| Control of intracellular pH and growth by fibronectin in capillary endothelial cells | Q36383431 | ||
| Control of cyclin D1, p27(Kip1), and cell cycle progression in human capillary endothelial cells by cell shape and cytoskeletal tension | Q36921506 | ||
| How does extracellular matrix control capillary morphogenesis? | Q38688053 | ||
| Redox changes of cultured endothelial cells and actin dynamics | Q40893463 | ||
| Externalization of tropomyosin isoform 5 in colon epithelial cells | Q40919176 | ||
| Tropomyosin isoforms in nonmuscle cells. | Q41322774 | ||
| Effects of angiogenesis inhibitors on multistage carcinogenesis in mice | Q41648802 | ||
| Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. | Q50626711 | ||
| Characterisation of the low affinity interaction between rat cell adhesion molecules CD2 and CD48 by analytical ultracentrifugation. | Q51606035 | ||
| The mechanics of vascular cell motility. | Q52181149 | ||
| Zinc ligand-disrupted recombinant human Endostatin: potent inhibition of tumor growth, safety and pharmacokinetic profile | Q52552160 | ||
| Stress-induced fractal rearrangement of the endothelial cell cytoskeleton causes apoptosis | Q57773654 | ||
| The Angiogenesis Inhibitor, Endostatin, Does Not Affect Murine Cutaneous Wound Healing | Q58376213 | ||
| Vascular endothelial growth factor-stimulated actin reorganization and migration of endothelial cells is regulated via the serine/threonine kinase Akt | Q64380808 | ||
| Geometric control of switching between growth, apoptosis, and differentiation during angiogenesis using micropatterned substrates | Q73028680 | ||
| Affinity and kinetic analysis of L-selectin (CD62L) binding to glycosylation-dependent cell-adhesion molecule-1 | Q74016257 | ||
| Endostatin induces endothelial cell apoptosis | Q77335987 | ||
| P433 | issue | 27 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 25190-25196 | |
| P577 | publication date | 2001-05-02 | |
| P1433 | published in | Journal of Biological Chemistry | Q867727 |
| P1476 | title | Endostatin binds tropomyosin. A potential modulator of the antitumor activity of endostatin | |
| P478 | volume | 276 |
| Q36821881 | A review on angiogenesis and its assays |
| Q47918559 | Accumulation of endostatin/collagenXVIII in brains of patients who died with cerebral malaria |
| Q35038768 | Angiogenesis as a target for cancer therapy |
| Q35008096 | Cellular actions and signaling by endostatin |
| Q35662667 | Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis) |
| Q35092178 | Delivery of endostatin in experimental cancer therapy. |
| Q40639238 | Design of a partial peptide mimetic of anginex with antiangiogenic and anticancer activity. |
| Q40456169 | Differential endostatin binding to bladder, prostate and kidney tumour vessels. |
| Q41352494 | E-M, an Engineered Endostatin with High ATPase Activity, Inhibits the Recruitment and Alternative Activation of Macrophages in Non-small Cell Lung Cancer |
| Q37389156 | Early genetic mechanisms underlying the inhibitory effects of endostatin and fumagillin on human endothelial cells |
| Q48073500 | Effects of intracavitary administration of Endostar combined with cisplatin in malignant pleural effusion and ascites |
| Q35800448 | Endogenous inhibitors of angiogenesis in malignant gliomas: nature's antiangiogenic therapy |
| Q35177609 | Endostatin action and intracellular signaling: beta-catenin as a potential target? |
| Q36578668 | Endostatin and endorepellin: A common route of action for similar angiostatic cancer avengers |
| Q34130059 | Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. |
| Q84977689 | Endostatin inhibits tumour lymphangiogenesis and lymphatic metastasis via cell surface nucleolin on lymphangiogenic endothelial cells |
| Q37971326 | Endostatin specifically targets both tumor blood vessels and lymphatic vessels |
| Q36406772 | Endothelial cell dysfunction and cytoskeletal changes associated with repression of p16(INK4a) during immortalization. |
| Q35849864 | Endothelial progenitor cells from infantile hemangioma and umbilical cord blood display unique cellular responses to endostatin. |
| Q35849729 | Endothelial-cell apoptosis induced by cleaved high-molecular-weight kininogen (HKa) is matrix dependent and requires the generation of reactive oxygen species |
| Q45884497 | Functional characterization of neostatins, the MMP-derived, enzymatic cleavage products of type XVIII collagen |
| Q35609350 | High serum level of endostatin in multiple myeloma at diagnosis but not in the plateau phase after treatment |
| Q78968682 | Human endostatin-derived synthetic peptides possess potent antiangiogenic properties in vitro and in vivo |
| Q35679496 | Improving the therapeutic potential of endostatin by fusing it with the BAX BH3 death domain. |
| Q84514042 | Inappropriate angiogenic response as a novel mechanism of duodenal ulceration and impaired healing |
| Q28508127 | Influence of endostatin on embryonic vasculo- and angiogenesis |
| Q36224981 | Inhibitory effect of endostatin combined with paclitaxel-cisplatin on breast cancer in xenograft-bearing mice |
| Q35742729 | KSHV MicroRNAs Repress Tropomyosin 1 and Increase Anchorage-Independent Growth and Endothelial Tube Formation |
| Q35551132 | Molecular basis of angiogenesis and cancer |
| Q34958987 | New functional roles for non-collagenous domains of basement membrane collagens |
| Q36893358 | New molecular mechanisms of duodenal ulceration |
| Q24317515 | Nucleolin is a receptor that mediates antiangiogenic and antitumor activity of endostatin |
| Q45831726 | Plasma levels of angiostatin and endostatin remain unchanged for the first 3 weeks after colorectal cancer surgery |
| Q35679807 | Proteolytically Derived Endogenous Angioinhibitors Originating from the Extracellular Matrix |
| Q31156798 | Screening and identification of mimotope of gastric cancer associated antigen MGb1-Ag |
| Q33203193 | Selection of a peptide mimicking neutralization epitope of hepatitis E virus with phage peptide display technology |
| Q39308829 | The Challenges of Recombinant Endostatin in Clinical Application: Focus on the Different Expression Systems and Molecular Bioengineering. |
| Q34155709 | The antiangiogenic activity of cleaved high molecular weight kininogen is mediated through binding to endothelial cell tropomyosin |
| Q36290509 | The clinical potential of antiangiogenic fragments of extracellular matrix proteins |
| Q54077957 | The nuclear translocation of endostatin is mediated by its receptor nucleolin in endothelial cells. |
| Q24811681 | The response of VEGF-stimulated endothelial cells to angiostatic molecules is substrate-dependent |
| Q89978052 | Tropomyosin: An Excretory/Secretory Protein from Haemonchus contortus Mediates the Immuno-Suppressive Potential of Goat Peripheral Blood Mononuclear Cells In Vitro |
| Q55465048 | [Combining bevacizumab with endostatin gets better antitumor efficacy in vivo in lung cancer animal model]. |
Search more.